Longeveron (LGVN) Total Current Liabilities (2021 - 2026)
Longeveron's (LGVN) quarterly Total Current Liabilities came in at $4.3 million in Q1 2026, up 59.51% year-on-year from $2.7 million in Q1 2025, and up 6.31% quarter-over-quarter from $4.1 million in Q4 2025.
Longeveron (LGVN) Total Current Liabilities (2021 - 2026) Analysis & Trends
Longeveron's Total Current Liabilities history runs 6 years deep, the most recent figure standing at $4.3 million for Q1 2026.
- On a quarterly basis, Total Current Liabilities rose 59.51% year-over-year to $4.3 million in Q1 2026; TTM through Mar 2026 was $4.3 million, a 59.51% increase from a year earlier, with the FY2025 full-year figure at $4.1 million, up 58.29% from the prior year.
- Total Current Liabilities advanced to $4.3 million in Q1 2026 per LGVN's latest filing, from $4.1 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $5.3 million in Q1 2024 and bottomed at $2.6 million in Q4 2024.
- The 5-year median for Total Current Liabilities is $3.7 million (2023), against an average of $3.8 million.
- Across the five-year window, Total Current Liabilities soared 79.8% in 2022 and slumped 48.56% in 2025, its largest moves.
- Year by year, Total Current Liabilities stood at $4.9 million in 2022, then decreased by 20.13% to $3.9 million in 2023, then slumped by 33.61% to $2.6 million in 2024, then soared by 58.29% to $4.1 million in 2025, then advanced by 6.31% to $4.3 million in 2026.
- Per Business Quant, the three latest LGVN Total Current Liabilities figures stand at $4.3 million (Q1 2026), $4.1 million (Q4 2025), and $4.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 56.01 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 66.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.81 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 6.38 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 3.88 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.11 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.58 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 289.60 Mn |
| 10 | Longeveron | 3.97 Mn | -11.79 Mn | 264,000.00 | 4.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.35 Mn |
| Dec 31, 2025 | 4.09 Mn |
| Sep 30, 2025 | 4.94 Mn |
| Jun 30, 2025 | 3.28 Mn |
| Mar 31, 2025 | 2.72 Mn |
| Dec 31, 2024 | 2.58 Mn |
| Sep 30, 2024 | 3.10 Mn |
| Jun 30, 2024 | 3.21 Mn |
| Mar 31, 2024 | 5.30 Mn |
| Dec 31, 2023 | 3.89 Mn |
| Sep 30, 2023 | 3.39 Mn |
| Jun 30, 2023 | 4.08 Mn |
| Mar 31, 2023 | 3.60 Mn |
| Dec 31, 2022 | 4.87 Mn |
| Dec 31, 2021 | 2.71 Mn |